HIV-1 GP120 CD4 binding site antibodies targeting HIV escape mutants

Patent metadata

Field	Value
Publication number	US-11149081-B2
Application number	US-201715835319-A
Country	US
Kind code	B2
Filing date	Dec 7, 2017
Priority date	Jun 21, 2012
Publication date	Oct 19, 2021
Grant date	Oct 19, 2021

Abstract

Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.

First claim

What is claimed is:

1. A composition comprising:
a human anti-CD4 binding site (anti-CD4bs) VRC01-related antibody variant having an isolated heavy chain and an isolated light chain,
the isolated heavy chain comprising:
a glycine (G) or a first substitution of G at position 54 of the isolated heavy chain according to Kabat numbering, the first substitution being selected from the group consisting of Gb54H, G54R, G54Q, G54N, G54K, G54E, G54D, G54W, G54Y, and G54F; and
a second substitution of tryptophan (W) at position 47 of the isolated heavy chain according to Kabat numbering, the second substitution being selected from the group consisting of W47V, W47I, and W47T, the VRC01-related antibody variant comprising:
a complementarity determining region (CDR) 1 of the heavy chain (CDRH1) having a sequence of Gly26-Tyr27-Glu28-Phe29-(Ile/Leu)30-(Asn/Asp)31-Cys32 (SEQ ID No: 77);
a CDR 2 of the heavy chain (CDRH2) having a sequence of Lys52-Pro52A-Arg53-(Gly/His/Arg/Gln/Asn/Lys/Glu/Asp/Trp/Tyr/Phe)54-Gly55-Ala56 (SEQ ID No: 78);
a CDR 3 of the heavy chain (CDRH3) having a sequence selected from: Gly95-Lys96-(Asn/Tyr)97-Cys98-(Asp/Thr)99-Tyr100-Asn100A-Trp100B-Asp100C-Phe100D-Glu101-His102 (SEQ ID No: 79) or Gly95-Lys96-(Asn/Tyr)97-Cys98-(Asp/Thr)99-Ala100- Arg100A-Asp100B-Tyr100C-Tyr100D-Asn100E-Trp100E-Asp100G-Phe100H-Glu101-His 102 (SEQ ID No: 80);
a CDR 1 of the light chain (CDRL1) having a sequence of Arg24-Thr25- Ser26-Gln27-(Ser/Tyr)28-Gly29-Ser30-Leu33-Ala34 (SEQ ID No: 81);
a CDR 2 of the light chain (CDRL2) having a sequence of Ser50-Gly51-Ser52-Thr53-Arg54-Ala55-Ala56 (SEQ ID No: 82); and
a CDR 3 of the light chain (CDRL3) having a sequence of Gln89-Gln90-Tyr91-Glu96-Phe97 (SEQ ID No: 83),

wherein the CDRs are defined according to the Chothia definition.

2. The composition of claim 1 , wherein the first substitution at position 54 is tryptophan, tyrosine, phenylalanine, histidine, arginine, glutamine, or asparagine.

3. A pharmaceutical composition comprising the composition human anti-CD4bs VRC01-related antibody variant of claim 1 or a fragment thereof, and a pharmaceutically acceptable carrier.

4. A method of inhibiting an HIV infection or an HIV-related disease, the method comprising administering a therapeutically effective amount of the composition of claim 1 to a patient.

5. A method of inhibiting an HIV infection or an HIV-related disease, the method comprising administering a therapeutically effective amount of a combination of antibodies, the combination of antibodies comprising a first antibody and a second antibody, the first antibody comprising the composition of claim 1 and the second antibody comprising 10-1074 antibody.

6. The composition of claim 1 , wherein the human anti-CD4bs VRC01-related antibody variant is capable of binding to gp120 at positions corresponding to 279, 280, 368, 458, and 459 according to pdb code 3U7Y.

7. The composition of claim 1 , wherein the isolated light chain comprises a substitution of tyrosine for serine at position 28 according to Kabat numbering.

Assignees

• California Inst Of Techn
• Univ Rockefeller

Inventors

• Diskin Ron
• West Anthony P
• Nussenzweig Michel C
• Bjorkman Pamela J

Classifications

• C07K16/114

  Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV] · CPC title

• C07K16/1145 Primary

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C12N2740/16111

  concerning HIV env · CPC title

• A61P31/18

  for HIV · CPC title

• A61K2039/505

  comprising antibodies · CPC title